4:58 PM ET
10-Q
Financial Results
Veradermics Q3 2026 Results: Net Loss of $21M, Loss Widens
Veradermics, Inc. is a clinical-stage biopharmaceutical company focused on developing VDPHL01 for pattern hair loss. As of November 5, 2026, the company had 42,195,472 shares of common stock outstanding and continues to incur substantial losses with no products yet approved for commercial sale.
- Key figure
- Net loss $21M